Neuroprotective efficacy of the 5HT1A agonist DU123015 and positive control MK-801 in the 60 minutes distal MCAo model. (A) The body weights of animals treated with DU123015 and glucosaline-treated controls. No significant differences between groups were observed. (B) The body weights for MK-801 and saline-treated controls. No significant differences between groups were observed. Neither DU123015 (C), nor MK-801 (D), significantly improve neurological functions, although on day 2 MK-801 almost significantly improved function (P = 0.056). (E) Oedema corrected MRI lesion volumes did not differ for DU123015-treated animals and glucosaline controls. (F) MK-801-treated animals exhibited a significant reduction in lesion volume at both time-points. (**) P < 0.01, (*) P < 0.05.